Pediatrics

Projects

Projects per year 2006 2009 2014 2016 2017 2018 2020 2021 2022 2023 2024 2029

• 38 Active
• 86 Completed

Projects per year

Search results

• Completed

  Collaboration of MenB Vaccination of Adolescents- Facilitating Category B Vaccine Discussion Within the 16 yo Immunization Platform

  Auslander, B. (PI)

  University of Oklahoma Health Science Center ( Award # )

  2/13/20 → 6/16/20

  Project: Research project

• Impedance oscillometry as predictor of asthma exacerbation requiring Emergency Room, Urgent Care visit or Hospitalization in children: A Retrospective study.

  Lindsay, D. (PI)

  Texas Allergy and Immunology Society ( Award # )

  2/1/20 → 12/31/21

  Project: Research project

• Hydrogen Sulfide and NRF2 Cross-talk in Viral Infections (Harvey Supplement)

  Casola, A. (PI)

  National Institute of Allergy and Infectious Diseases ( Award #3R01AI12543403S1)

  6/1/19 → 5/31/20

  Project: Research project

• A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4 -dose Regimen of V114 in Healthy Infants (PNEU-PED)

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  4/25/19 → 4/24/23

  Project: Research project

• Modulation of the Allergenicity of Cedar and Ragweed Pollen Major Allergens

  Midoro-Horiuti, T. (PI)

  National Institute of Allergy and Infectious Diseases ( Award #5R21AI14256902)

  12/1/18 → 11/30/22

  Project: Research project

• A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13¿ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  9/14/18 → 9/13/21

  Project: Research project

• Comprehensive Analysis of CMV-specific T cells in Human Subjects Receiving a Replication-defective Human Cytomegalovirus Vaccine

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  8/28/18 → 8/27/22

  Project: Research project

• A Phase IIIB, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine

  Rupp, R. (PI)

  Corixa Corporation ( Award # )

  7/9/18 → 7/8/20

  Project: Research project

• A PHASE 2, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN WITH, OR SEPARATELY FROM, 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

  Rupp, R. (PI)

  ICON Clinical Research, LLC ( Award # )

  7/5/18 → 7/4/23

  Project: Research project

• A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  7/2/18 → 7/1/23

  Project: Research project

• A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX¿23 Six Months Later in Immunocompetent Adults Between 18 and 49 Y

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  7/1/18 → 6/30/23

  Project: Research project

• A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX¿23 One Year Later in Healthy Adults 50 Years of Age or Older (PN

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  6/11/18 → 6/10/23

  Project: Research project

• A Phase III, partially modified double-blind, randomized, parallel-group, active-controlled, multi-center study to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when administered concomitantly with routine pe

  Rupp, R. (PI)

  Sanofi Pasteur, Inc ( Award # )

  5/2/18 → 5/1/23

  Project: Research project

• An Expanded Access Treatment Protocol for Zmapp TM for Patients with Ebola Virus Disease (EVD) or Ebola Virus Exposure

  Rupp, R. (PI)

  ICON Government and Public Health Solutions ( Award #HHSO100201600021C)

  5/1/18 → 6/26/19

  Project: Research project

• Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  4/24/18 → 4/23/23

  Project: Research project

• A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

  Rupp, R. (PI)

  Pfizer, Inc ( Award # )

  3/30/18 → 3/29/21

  Project: Research project

• Protocol 63623872FLZ3002: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized

  Rupp, R. (PI)

  Janssen Pharmaceutical Research and Development ( Award #HHSO1002OI500014C)

  2/5/18 → 12/31/20

  Project: Research project

• A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Live-Attenuated Tetravalent Dengue Vaccine (V181) in Flavivirus-Naive and Flavivirus-Experienced Health Adults (MK-V181-001-01)

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  1/4/18 → 1/3/21

  Project: Research project

• IMPAACT 2021 startup

  Rupp, R. (PI)

  Johns Hopkins University ( Award #5UM1AI06863214)

  1/1/18 → 11/30/20

  Project: Research project

• A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 (PE34) Process Administered Concomitantly with M-M-R II

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  8/21/17 → 8/20/19

  Project: Research project

• lmmunogenicity, reactogenicityan safety study of Pediarix, Hiberix, and Prevnar 13 co-administered with two diff'erent formulations of GSK Biologicals' HRVvaccine ( 444563) in healthy infants 6-12 weeks of age

  Rupp, R. (PI)

  GlaxoSmithKline Pharmaceuticals ( Award # )

  8/18/17 → 8/17/19

  Project: Research project

• Task B- Base Period

  Rupp, R. (PI)

  Baylor College of Medicine ( Award #HHSN272201300015I)

  7/28/17 → 2/28/21

  Project: Research project

• HSV testing in animal models

  Bourne, N. (PI)

  Conrad ( Award #AIDOAAA1400010)

  5/1/17 → 10/15/18

  Project: Research project

• A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar13 in Healthy Infants

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  2/8/17 → 2/7/21

  Project: Research project

• A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114

  Wolffarth, M. (PI)

  Merck and Company ( Award # )

  2/8/17 → 8/7/20

  Project: Research project

• A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDEDS TUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER

  Rupp, R. (PI)

  Pfizer, Inc ( Award # )

  2/7/17 → 2/6/23

  Project: Research project

• Role of Hydrogen Sulfide in Viral Infections

  Casola, A. (PI)

  National Institute of Allergy and Infectious Diseases ( Award #5R21AI12214202)

  12/1/16 → 11/30/19

  Project: Research project

• GV29893 A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, ADMINISTERED AS MONOTHERAPY FOR THE TREATMENT OF ACUTE UNCOMPLICATED SEASONAL INFLUENZA A INFECTION IN OTHERWISE HEALTHY ADULTS

  Rupp, R. (PI)

  Genentech, Inc ( Award # )

  10/27/16 → 10/26/18

  Project: Research project

• Vaccine and Treatment Evaluation Units (VTEU) Protocol Development, Implementation and Assays Task Area B-D Task Order 15-0066.B1C1D1.0041

  Rupp, R. (PI)

  Baylor College of Medicine ( Award #HHSN272201300015I)

  9/16/16 → 2/28/21

  Project: Research project

• (GSK ARIOS) follow-Up study to assess Long-Term safety and outcomes in infants and children born to mothers participating in Retosiban Treatment Studies

  Jain, S. (PI)

  GlaxoSmithKline Pharmaceuticals ( Award # )

  9/16/16 → 9/15/18

  Project: Research project

• The VesiVax System: Vaccine Development Made Easy

  Bourne, N. (PI)

  Molecular Express, Inc ( Award #2R44AI09477003A1)

  8/1/16 → 7/31/18

  Project: Research project

• Zika Virus Recombinant Subunit Vaccine

  Bourne, N. (PI)

  Hawaii Biotech, Inc ( Award # )

  7/1/16 → 6/1/17

  Project: Research project

• The Dynamics of Nasal Bacterial Ecology and S. aureus Antagonism

  Pyles, R. (PI)

  George Washington University ( Award #5R01AI12556204)

  6/1/16 → 5/31/20

  Project: Research project

• Role of the endogenous gasotransmitter H2S in ETS-mediated airway disease

  Garofalo, R. P. (PI)

  National Institute of Environmental Health Sciences ( Award #5R21ES02678202)

  6/1/16 → 5/31/19

  Project: Research project

• Hydrogen Sulfide Donors As Broad Antiviral Treatment For RNA Viruses

  Casola, A. (PI)

  Sanofi-Aventis US ( Award # )

  12/15/15 → 12/14/16

  Project: Research project

• Role of tRNA-derived RNA Fragments (tRFs) in Respiratory Syncytial Virus (RSV) Infection

  Bao, X. (PI)

  National Institute of Allergy and Infectious Diseases ( Award #5R01AI11681205)

  12/1/15 → 11/30/21

  Project: Research project

• V114-005 A Phase l-ll, randomized, Double-Blind, Study to Evaluate the safety, Tolerability, and Immunogenicity of Different formulations of V114 in Healthy Adults and Infants

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  8/18/15 → 8/17/18

  Project: Research project

• A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lots and a high Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  8/4/15 → 9/30/18

  Project: Research project

• EL II: Functional Portraits of tRNA-derived Small Non-coding RNAs

  Bao, X. (PI)

  National Institute of Allergy and Infectious Diseases ( Award #5R21AI11377102)

  6/15/15 → 5/31/17

  Project: Research project

• Respiratory Syncytial Virus Utilizes a tRNA 5¿-end Fragment to Suppress Host antiviral Response

  Bao, X. (PI)

  American Thoracic Society ( Award # )

  11/30/14 → 11/29/16

  Project: Research project

• EL II: Engineering of a Novel CDN Nanoparticle Platform

  Bourne, N. (PI)

  Molecular Express, Inc ( Award #1R43AI11213201A1)

  9/1/14 → 9/30/15

  Project: Research project

• Enviromental estrogens induced signals in immune cells that promote the development of asthma

  Midoro-Horiuti, T. (PI)

  American Lung Association - New York ( Award #AI310304)

  9/1/14 → 8/31/16

  Project: Research project

• EL II: Anti-HIV/SHIV Efficacy of Combination Antiretroviral Intravaginal Rings

  Pyles, R. (PI)

  Oak Crest Institute of Science ( Award #5U19AI11304805)

  8/11/14 → 7/31/19

  Project: Research project

• V160-001-002: A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  6/27/14 → 6/26/18

  Project: Research project

• A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of VARIVAX New Seed Process (NSP) Administered Concomitantly with M-M-R II

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  4/30/14 → 5/1/16

  Project: Research project

• Antibiotic Safety in Infants with Complicated Intra-Abdominal Infections

  Shattuck, K. (PI)

  DUKE UNIVERSITY

  3/27/14 → 9/23/17

  Project: Research project

• V503-010-0007: A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, administered in Preadolescents and Adolescents (9 to 14 yea

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  2/7/14 → 2/6/19

  Project: Research project

• A 48-52 Month Blinded-Outcomes Follow up Study of Patients Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-205

  Shattuck, K. (PI)

  Quintiles, Inc.

  12/6/13 → 12/5/19

  Project: Research project

• CE01-119: A Phase 1, Open-label, Multi-center Study to Determine the Pharmacokinetics and Safety of Solithromycin as Add-on Therapy in Adolescents with Suspected or Confirmed Bacterial Infection

  Aigbivbalu, L. (PI)

  Duke University ( Award #HHSO100201300009C)

  12/5/13 → 5/23/15

  Project: Research project

• ELII: Antiviral Innate Pathways and Superoxide Dismutase in RSV Bronchiolitis

  Garofalo, R. P. (PI)

  National Institute of Allergy and Infectious Diseases ( Award #5R21AI10908802)

  12/4/13 → 11/30/16

  Project: Research project